Biomerica Inc (BMRA) 0.9800 $BMRA
Biomerica Announces Conference Call Regarding Its Product and Recent Developments in the Irritable Bowel Syndrome (IBS) Market
Marketwired - Mon Jul 06, 7:18AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, will hold a conference call to discuss its product and recent developments in the Irritable Bowel Syndrome (IBS) market on Wednesday, July 8 at 1:30 pm Pacific Time (4:30 Eastern Time). The call will be hosted by Zack Irani-Cohen, Biomerica's Chief Executive Officer.
Biomerica reports new distribution channel in Brazil upon ANVISA approvals
M2 - Tue Jun 30, 6:06AM CDT
Biomedical company Biomerica (OTCBB:BMRA) disclosed on Monday the receipt of its first Brazilian ANVISA approvals for several of its clinical lab products.
Biomerica Announces Its First Brazilian ANVISA Approvals and a New Distribution Channel in Brazil
Marketwired - Mon Jun 29, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA) today announced that it received its first Brazilian ANVISA approvals for several of its clinical lab products. ANVISA is Brazil's equivalent to the US FDA, and is responsible for the oversight of all pharmaceuticals and medical devices in the Brazilian market. The approved products will be distributed through a new Brazilian distribution partner. Several other Biomerica product approvals are pending.
Global Rapid Medical Diagnostic Kits Market - Applications and Technologies Analysis of the $27 Billion Industry
M2 - Mon May 25, 10:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v48zr8/global_rapid) has announced the addition of the "Global Rapid Medical Diagnostic Kits Market - Applications and Technologies" report to their offering. lobal market for Rapid Medical Diagnostic Kits, estimated at US$19.4 billion in 2014, forecast at US$20.4 billion in 2015 and further expected to maintain a CAGR of 5.7% between 2014 and 2020 to reach a projected US$27 billion by 2020. The global market for Rapid Medical Diagnostic Kits (MDKs) has been witnessing steady, albeit not rapidly accelerated, growth over the past few years, and this trend is likely to sustain over the coming years. One of the major factors that can be attributed to this is the quick time, typically inside of 30 minutes, within which test results can be made available. This helps physicians in expediting the therapy process for individuals by prescribing the appropriate medications within a short period of time. Gone are the days when doctors had to rely on out-of-office laboratories, which more often than not took days, if not weeks, in processing and providing test results. Now, a clinical test using a sample from the patient can be performed within a physician's office, the specimen sent to an in-house laboratory and results obtained while the patient waits. Worldwide market for Rapid Medical Diagnostic Kits application segments explored in this study includes Clinical Testing, Home-Based Testing and Veterinary Testing. These broader application segments further analyzed for the applications areas of Blood Glucose, Cholesterol, Fertility & Pregnancy, Infectious Disease and Substance Abuse. The report also focuses on the technologies of Rapid Medical Diagnostic Kits comprising Agglutination, Flow-Through, Lateral Flow and Solid-Phase. The global markets for the above mentioned application segments and diagnostic technologies are analyzed in terms of USD. G This report reviews, analyses and projects the Rapid Medical Diagnostic Kits market for global and the regional markets including North America, Europe, Asia-Pacific, South America and Rest of World. The regional markets further analyzed for 14 independent countries across North America - The United States, Canada and Mexico; Europe - France, Germany, Italy, Spain and the United Kingdom; Asia-Pacific -China, India, Japan and South Korea; South America - Argentina and Brazil. This report profiles 42 key global players and 55 major players across North America - 39; Europe - 7; and Asia-Pacific - 9. The research also provides the listing of the companies engaged in manufacturing and supply of Rapid MDKs. The global list of companies covers addresses, contact numbers and the website addresses of 193 companies. Key Topics Covered: Part A: Global Market Perspective 1. Introduction 2. Key Market Trends 3. Key Global Players 4. Key Business Trends 5. Global Market Overview Part B: Regional Market Perspective Regional Market Overview 1. North America 2. Europe 3. Asia-Pacific 4. South America 5. Rest Of World Part C: Guide To The Industry 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part
Annexure 1. Research Methodology 2. Feedback Companies Mentioned - Abbott Laboratories, Inc - Alfa Scientific Designs, Inc - Arkray USA Inc - Beckman Coulter Inc - Becton, Dickinson And Company - Biomerica, Inc - Biom?rieux SA - Bio-Rad Laboratories, Inc - Diagnostic Automation / Cortez Diagnostics Inc - EKF Diagnostics Holdings Plc - Enzo Life Sciences, Inc - F. Hoffmann-La Roche Ltd - IDEXX Laboratories, Inc - Immunostics, Inc - Inbios International, Inc - Jant Pharmacal Corporation - Labsystems Diagnostics OY - Lifescan, Inc - Princeton Biomeditech Corporation - Quidel Corporation - Rapid Diagnostic Pvt. Ltd - Roche Diagnostics Corporation - Runbio Biotech Co., Ltd. - SA Scientific, Inc - Sekisui Diagnostics, LLC - Shanghai Kehua Bio-Engineering Co., Ltd (KHB) - Siemens Healthcare - Standard Diagnostics, Inc - Taidoc Technology Corporation - Thermo Fisher Scientific Inc - Zoetis, Inc For more information visit http://www.researchandmarkets.com/research/v4...obal_rapid
ZTS: 46.96 (+0.39), ABT: 49.93 (+0.74), IDXX: 64.09 (+1.22)
Biomerica Announces Third Quarter Financial Results and Establishes Scientific Advisory Board
Marketwired - Wed Apr 15, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA) today reported net sales of $3,467,450 for the nine months ending February 28, 2015, compared to $3,441,299 for the same period in the previous year. Sales for the three months ending February 28, 2015 were $1,299,400 compared to $1,492,719 for the same period last year.
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.32 (+0.82), IMMU: 4.20 (+0.24), A: 39.40 (+0.48), INCY: 108.33 (+0.22), LLY: 88.29 (+0.81), ONTY: 3.66 (+0.04), VRML: 1.96 (+0.04), AFFX: 11.05 (+0.26), SQNM: 2.95 (+0.11), OPK: 16.55 (-0.01)
Biomerica Announces Second Quarter Financial Results
Marketwired - Thu Jan 15, 7:19AM CST
Biomerica, Inc. (OTCBB: BMRA) today reported net sales of $1,133,600 for the three months ended November 30, 2014, compared to $934,841 for the same period in the previous year, an increase of 21.3%. Net sales were $2,168,050 for the first six months of fiscal 2015 compared to $1,948,580 for the first six months in fiscal 2014, an increase of 11.3% .
Biomerica Has Filed a First Set of Patent Applications With the USPTO for a New Test to Aid in the Treatment of a Gastrointestinal Disorder
Marketwired - Wed Jan 14, 7:19AM CST
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced today that it has filed a first set of patent applications with the U.S. Patent and Trademark Office for a new test intended to aid in the treatment of a specific gastrointestinal disorder.
Biomerica posts higher Q1 net loss of USD219,268
M2 - Fri Oct 17, 7:13AM CDT
Diagnostic products company Biomerica (OTCBB:BMRA) stated on Thursday that its net loss was USD219,268 for the first fiscal quarter ended 31 August 2014.
Biomerica fiscal Q1 results
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:00AM CDT
Biomerica Reports First Quarter Results
Marketwired - Thu Oct 16, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced financial results today for the first fiscal quarter ended August 31, 2014.
Biomerica Announces Year End Results
Marketwire - Tue Sep 02, 6:47AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported net sales for the fiscal year 2014 were $5,120,451 versus net sales of $6,472,960 in fiscal 2013. Net loss was $215,660 for fiscal 2014 compared to net income of $536,957 for fiscal 2013. Net sales for the fourth quarter ended May 31, 2014 were $1,679,152 versus net sales of $1,470,542 in the same fiscal quarter 2013. The pre-tax net loss for the fourth quarter fiscal 2014 was $51,423 compared to net income of $19,138 for fiscal 2013. Research and Development spending was $589,866 for fiscal year 2014 compared to $459,086 the previous year, an increase of $130,780.
Biomerica to Supply Its Colorectal Screening Point of Care Test to Multinational Pharmaceutical Company With Over $40 Billion in Sales
Marketwire - Mon Aug 11, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA) announced today it will supply its EZ Detect colorectal screening test to a multinational pharmaceutical company that has over $40 billion in revenues and over 70,000 employees worldwide. The EZ Detect product will be sold and marketed by the pharmaceutical company in one European country with the possibility of expanding into multiple other countries throughout Europe. The same pharmaceutical company currently distributes two other Biomerica point of care tests and the colorectal screening test is a new addition to the line. The terms of the agreement were not disclosed and will remain confidential.
Biomerica Announces Conference Call Regarding Its Product and Recent Developments in the Irritable Bowel Syndrome (IBS) Market
Marketwired - Mon Jul 06, 7:18AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, will hold a conference call to discuss its product and recent developments in the Irritable Bowel Syndrome (IBS) market on Wednesday, July 8 at 1:30 pm Pacific Time (4:30 Eastern Time). The call will be hosted by Zack Irani-Cohen, Biomerica's Chief Executive Officer.
Biomerica reports new distribution channel in Brazil upon ANVISA approvals
M2 - Tue Jun 30, 6:06AM CDT
Biomedical company Biomerica (OTCBB:BMRA) disclosed on Monday the receipt of its first Brazilian ANVISA approvals for several of its clinical lab products.
Biomerica Announces Its First Brazilian ANVISA Approvals and a New Distribution Channel in Brazil
Marketwired - Mon Jun 29, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA) today announced that it received its first Brazilian ANVISA approvals for several of its clinical lab products. ANVISA is Brazil's equivalent to the US FDA, and is responsible for the oversight of all pharmaceuticals and medical devices in the Brazilian market. The approved products will be distributed through a new Brazilian distribution partner. Several other Biomerica product approvals are pending.
Global Rapid Medical Diagnostic Kits Market - Applications and Technologies Analysis of the $27 Billion Industry
M2 - Mon May 25, 10:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v48zr8/global_rapid) has announced the addition of the "Global Rapid Medical Diagnostic Kits Market - Applications and Technologies" report to their offering. lobal market for Rapid Medical Diagnostic Kits, estimated at US$19.4 billion in 2014, forecast at US$20.4 billion in 2015 and further expected to maintain a CAGR of 5.7% between 2014 and 2020 to reach a projected US$27 billion by 2020. The global market for Rapid Medical Diagnostic Kits (MDKs) has been witnessing steady, albeit not rapidly accelerated, growth over the past few years, and this trend is likely to sustain over the coming years. One of the major factors that can be attributed to this is the quick time, typically inside of 30 minutes, within which test results can be made available. This helps physicians in expediting the therapy process for individuals by prescribing the appropriate medications within a short period of time. Gone are the days when doctors had to rely on out-of-office laboratories, which more often than not took days, if not weeks, in processing and providing test results. Now, a clinical test using a sample from the patient can be performed within a physician's office, the specimen sent to an in-house laboratory and results obtained while the patient waits. Worldwide market for Rapid Medical Diagnostic Kits application segments explored in this study includes Clinical Testing, Home-Based Testing and Veterinary Testing. These broader application segments further analyzed for the applications areas of Blood Glucose, Cholesterol, Fertility & Pregnancy, Infectious Disease and Substance Abuse. The report also focuses on the technologies of Rapid Medical Diagnostic Kits comprising Agglutination, Flow-Through, Lateral Flow and Solid-Phase. The global markets for the above mentioned application segments and diagnostic technologies are analyzed in terms of USD. G This report reviews, analyses and projects the Rapid Medical Diagnostic Kits market for global and the regional markets including North America, Europe, Asia-Pacific, South America and Rest of World. The regional markets further analyzed for 14 independent countries across North America - The United States, Canada and Mexico; Europe - France, Germany, Italy, Spain and the United Kingdom; Asia-Pacific -China, India, Japan and South Korea; South America - Argentina and Brazil. This report profiles 42 key global players and 55 major players across North America - 39; Europe - 7; and Asia-Pacific - 9. The research also provides the listing of the companies engaged in manufacturing and supply of Rapid MDKs. The global list of companies covers addresses, contact numbers and the website addresses of 193 companies. Key Topics Covered: Part A: Global Market Perspective 1. Introduction 2. Key Market Trends 3. Key Global Players 4. Key Business Trends 5. Global Market Overview Part B: Regional Market Perspective Regional Market Overview 1. North America 2. Europe 3. Asia-Pacific 4. South America 5. Rest Of World Part C: Guide To The Industry 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part
Annexure 1. Research Methodology 2. Feedback Companies Mentioned - Abbott Laboratories, Inc - Alfa Scientific Designs, Inc - Arkray USA Inc - Beckman Coulter Inc - Becton, Dickinson And Company - Biomerica, Inc - Biom?rieux SA - Bio-Rad Laboratories, Inc - Diagnostic Automation / Cortez Diagnostics Inc - EKF Diagnostics Holdings Plc - Enzo Life Sciences, Inc - F. Hoffmann-La Roche Ltd - IDEXX Laboratories, Inc - Immunostics, Inc - Inbios International, Inc - Jant Pharmacal Corporation - Labsystems Diagnostics OY - Lifescan, Inc - Princeton Biomeditech Corporation - Quidel Corporation - Rapid Diagnostic Pvt. Ltd - Roche Diagnostics Corporation - Runbio Biotech Co., Ltd. - SA Scientific, Inc - Sekisui Diagnostics, LLC - Shanghai Kehua Bio-Engineering Co., Ltd (KHB) - Siemens Healthcare - Standard Diagnostics, Inc - Taidoc Technology Corporation - Thermo Fisher Scientific Inc - Zoetis, Inc For more information visit http://www.researchandmarkets.com/research/v4...obal_rapid ZTS: 46.96 (+0.39), ABT: 49.93 (+0.74), IDXX: 64.09 (+1.22)
Biomerica Announces Third Quarter Financial Results and Establishes Scientific Advisory Board
Marketwired - Wed Apr 15, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA) today reported net sales of $3,467,450 for the nine months ending February 28, 2015, compared to $3,441,299 for the same period in the previous year. Sales for the three months ending February 28, 2015 were $1,299,400 compared to $1,492,719 for the same period last year.
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.32 (+0.82), IMMU: 4.20 (+0.24), A: 39.40 (+0.48), INCY: 108.33 (+0.22), LLY: 88.29 (+0.81), ONTY: 3.66 (+0.04), VRML: 1.96 (+0.04), AFFX: 11.05 (+0.26), SQNM: 2.95 (+0.11), OPK: 16.55 (-0.01)
Biomerica Announces Second Quarter Financial Results
Marketwired - Thu Jan 15, 7:19AM CST
Biomerica, Inc. (OTCBB: BMRA) today reported net sales of $1,133,600 for the three months ended November 30, 2014, compared to $934,841 for the same period in the previous year, an increase of 21.3%. Net sales were $2,168,050 for the first six months of fiscal 2015 compared to $1,948,580 for the first six months in fiscal 2014, an increase of 11.3% .
Biomerica Has Filed a First Set of Patent Applications With the USPTO for a New Test to Aid in the Treatment of a Gastrointestinal Disorder
Marketwired - Wed Jan 14, 7:19AM CST
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced today that it has filed a first set of patent applications with the U.S. Patent and Trademark Office for a new test intended to aid in the treatment of a specific gastrointestinal disorder.
Biomerica posts higher Q1 net loss of USD219,268
M2 - Fri Oct 17, 7:13AM CDT
Diagnostic products company Biomerica (OTCBB:BMRA) stated on Thursday that its net loss was USD219,268 for the first fiscal quarter ended 31 August 2014.
Biomerica fiscal Q1 results
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:00AM CDT
Biomerica Reports First Quarter Results
Marketwired - Thu Oct 16, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, announced financial results today for the first fiscal quarter ended August 31, 2014.
Biomerica Announces Year End Results
Marketwire - Tue Sep 02, 6:47AM CDT
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported net sales for the fiscal year 2014 were $5,120,451 versus net sales of $6,472,960 in fiscal 2013. Net loss was $215,660 for fiscal 2014 compared to net income of $536,957 for fiscal 2013. Net sales for the fourth quarter ended May 31, 2014 were $1,679,152 versus net sales of $1,470,542 in the same fiscal quarter 2013. The pre-tax net loss for the fourth quarter fiscal 2014 was $51,423 compared to net income of $19,138 for fiscal 2013. Research and Development spending was $589,866 for fiscal year 2014 compared to $459,086 the previous year, an increase of $130,780.
Biomerica to Supply Its Colorectal Screening Point of Care Test to Multinational Pharmaceutical Company With Over $40 Billion in Sales
Marketwire - Mon Aug 11, 7:19AM CDT
Biomerica, Inc. (OTCBB: BMRA) announced today it will supply its EZ Detect colorectal screening test to a multinational pharmaceutical company that has over $40 billion in revenues and over 70,000 employees worldwide. The EZ Detect product will be sold and marketed by the pharmaceutical company in one European country with the possibility of expanding into multiple other countries throughout Europe. The same pharmaceutical company currently distributes two other Biomerica point of care tests and the colorectal screening test is a new addition to the line. The terms of the agreement were not disclosed and will remain confidential.
